Switzerland· 68706001
IMJUDO
A tremelimumab product containing tremelimumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Tremelimumab is registered in 16 of 19 countries.
Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 9 of them publish a price we can compare per daily dose
Tremelimumab · ATC L01FX20
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tremelimumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- Switzerland: $779.98 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Tremelimumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$779.98
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- tremelimumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01FX20
- ATC class
- Tremelimumab
- Defined daily dose
- 10.7 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680687060011Vial 1 StkCHF 1550.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tremelimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMJUDOAstraZeneca Pharmaceuticals LP
- SpainIMJUDO 20 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONAstrazeneca Ab
- BelgiumImjudo 20 mg/mlAstraZeneca
- FinlandIMJUDOAstraZeneca AB
- Japanトレメリムマブ(遺伝子組換え)アストラゼネカ
- SwedenIMJUDO 20 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- CzechiaIMJUDOAstraZeneca AB, Södertälje
- IrelandIMJUDO 20 mg/ml concentrate for solution for infusionAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imjudo
- Liechtenstein · Imjudo
- Norway · Imjudo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef5b4cdc-4f6b-4965-bd03-4eb72d2eb6d4 GET /v1/drugs/ef5b4cdc-4f6b-4965-bd03-4eb72d2eb6d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "tremelimumabum 25 mg",
"valid_from": "2025-05-01",
"limitations": "[{\"description\":\"<b>HCC</b><br>\\nIMJUDO in Kombination mit IMFINZI wird vergütet zur Behandlung von Patienten mit inoperablem hepatozellulärem Karzinom (HCC), die noch keine systemische Vorbehandlung erhalten haben, nicht für eine lokoregionale Therapie geeignet sind und folgende Kriterien erfüllen:<br>\\n• Erhaltene Leberfunktion (Child-Pugh-Klasse A)<br>\\n• ECOG Performance Status 0 oder 1<br>\\nDem Krankenversicherer ist bei Therapiebeginn die Indikation (inkl. Indikationscode) mitzuteilen. IMJUDO darf nur einmalig im ersten Therapiezyklus in Kombination mit IMFINZI verabreicht werden. Die Patienten können mit IMFINZI bis zur Progression der Erkrankung behandelt werden. Klinisch stabile Patienten mit initialem Befund einer Progression können bis zur Bestätigung der Progression der Erkrankung weiter behandelt werden.<br>\\nDie Zulassungsinhaberin AstraZeneca AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, für jede bezogene Packung IMJUDO und IMFINZI für die Indikation HCC einen festgelegten Anteil des Fabrikabgabepreises zurück. Die AstraZeneca AG gibt dem Krankenversicherer die wirtschaftlichen Preise für IMJUDO und IMFINZI bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil der Fabrikabgabepreise zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Indikationscode ist an den Krankenversicherer zu übermitteln: 21691.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21691.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-05-01\",\"validTo\":\"2027-04-30\"}]",
"galenic_form": "Inf Konz 25 mg / 1.25 ml",
"therapeutic_area": null,
"sl_inclusion_date": "2025-05-01",
"self_retention_pct": 10
}See everything about tremelimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.